Skip to content

Crocus Sativus Extract Impact in Metabolic Control of Patients With Diabetes Mellitus Type 1

Investigation of the Impact of the Administration of Crocus Sativus L Extract on the Metabolic Control of Patients With Type 1 Diabetes Mellitus

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05933460
Enrollment
61
Registered
2023-07-06
Start date
2022-03-01
Completion date
2023-04-28
Last updated
2025-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1, Diabetes type1

Keywords

diabetes mellitus type 1, diabetes type 1, saffron, saffron extract, continuous glucose monitoring

Brief summary

Administration of 4 strain of probiotics, prebiotic, magnesium and crocus sativus extract in a sachet to people with diabetes mellitus type 1 for 6 months

Detailed description

Double blind placebo controlled randomized trial: A sachet of a combination of 4 strains of probiotics (Lactobacillus rhamnosus, Bifidobacterium animalis lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides, Magnesium and Saffron extract was administered 3 times per day in people with diabetes type 1 for 6 months on continuous glucose monitoring systems.

Interventions

DIETARY_SUPPLEMENTdietary supplement with probiotics, prebiotics, magnesium and saffron extract

A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg and Saffron extract 28mg was administered 3 times per day

DIETARY_SUPPLEMENTdietary supplement with probiotics, prebiotics, magnesium

A sachet of a combination of 4 strains of probiotics (1billion CFU) (Lactobacillus rhamnosus, Bifidobacterium animalis subscp. lactis, Bifidobacterium breve, Bifidobacterium longum), Fructooligosaccharides 100mg, Magnesium 75mg was administered 3 times per day

Sponsors

Aristotle University Of Thessaloniki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

No participant or personnel knew the randomization process and the only knew did not had to do with participants or administration of supplement or collecting data. The company providing the supplement did not know either.

Intervention model description

Double blind placebo controlled randomized trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* People with diabetes mellitus type 1 (with diabetes duration over 1 year) (adults \<18 years old) wearing a continuous glucose monitoring system with or without an insulin pump

Exclusion criteria

* Pregnant * People with diabetes mellitus type 2 * Breastfeeding women * People with liver disease * People with chronic kidney disease (over stage 3) * People with allergy in crocus sativus * People that consume everyday herbs or supplements * People on anti platelet treatment not for prevention

Design outcomes

Primary

MeasureTime frameDescription
Diastolic Blood pressure6 monthsDiastolic blood pressure mmHg
glycated hemoglobin6 monthsglycated hemoglobin %
blood glucose6 monthsFasting blood glucose (mg/dl)
serum cholesterol6 monthsTotal Cholesterol mg/dl
serum High density lipoprotein cholesterol6 monthsHigh density lipoprotein Cholesterol mg/dl
serum low density lipoprotein cholesterol6 monthsLow density lipoprotein cholesterol mg/dl
triglycerides6 monthsserum Triglycerides mg/dl
Systolic Blood pressure6 monthsSystolic blood pressure mmHg

Secondary

MeasureTime frameDescription
Continuous glucose monitoring data6 monthsTime in range %
Continuous glucose monitoring time6 monthsTime below range %
Continuous glucose monitoring time data6 monthsTime above range %
Continuous glucose monitoring glycemic data6 monthsGlucose Management Indicator %
Continuous glucose monitoring statistic data6 monthsCoefficient of variance
Sural nerve conduction velocity6 monthsNerve conduction velocity is measured in the sural sensory nerve of both feet with Neurometrix DPNCheck
Electrochemical skin conductance6 monthsSudomotor function was assessed with SUDOSCAN, which measures electrochemical skin conductance in the feet (ESCF) and hands (ESCH)
Cardiovascular Autonomic Reflex tests6 monthsAutonomic neuropathy testing included cardiovascular autonomic reflex tests (CARTs) such as heart rate variability to obtain mean circular resultant (MCR), and the 30:15 stand up test to obtain postural index and blood pressure measurement to test for orthostatic hypotension

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026